| Mr David G Saccoccio, RPH | |
|
446 Putnam Pike, Greenville, RI 02828-3054 | |
| (401) 949-1848 | |
| Not Available |
| Full Name | Mr David G Saccoccio |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 446 Putnam Pike, Greenville, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427644418 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RPH03206 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr David G Saccoccio, RPH 146 Scituate Ave, Johnston, RI 02919-6004 Ph: (401) 946-3809 | Mr David G Saccoccio, RPH 446 Putnam Pike, Greenville, RI 02828-3054 Ph: (401) 949-1848 |
News Archive
It should be possible to use therapeutic vaccines to create both cheap and effective drugs for diseases like cancer and allergies. One problem in developing such vaccines has previously been the lack of adjuvants, substances that make vaccines more effective. However, there has now been a major breakthrough in this area. The study, led by Swedish scientists at Uppsala University, is published in the December issue of the journal Vaccine.
A day after Haitian President Rene Preval signed a decree authorizing a date for November elections, he rebuffed other recommendations issued by the U.S. Senate, which include "holding an election for his successor, brushing off criticism that the current process will leave the shattered country without a credible leader," the Associated Press reports.
A new strategic plan from an arm of the National Institutes of Health envisions scientists being able to identify genetic bases of most single-gene disorders and gaining new insights into multi-gene disorders in the next decade. This should lead to more accurate diagnoses, new drug targets and the development of practical treatments for many who today lack therapeutic options, according to the plan from the National Human Genome Research Institute (NHGRI).
Inhibitex, Inc., announced today that it has completed enrollment in a Phase II clinical trial of FV-100 in shingles (herpes zoster) patients. The objectives of the trial are to further evaluate the safety of FV-100 and its potential therapeutic benefit in reducing the severity and duration of shingles-associated pain, the incidence of post herpetic neuralgia (PHN), and the time to heal shingles-related lesions.
Asthmatic children in New York City neighborhoods with high rates of asthma make many more visits to the emergency room (ER) than those who live in other parts of the city. While socioeconomic factors such as lack of adequate preventive care are part of the equation (high-asthma neighborhoods tend to be lower income), new research points to a possible biological basis for the disparity.
› Verified 6 days ago
Alexis M Bolvin, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 452 Putnam Pike, Greenville, RI 02828 Phone: 401-949-6212 | |
Wendy Davis, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 445 Putnam Pike, Greenville, RI 02828 Phone: 401-231-5320 Fax: 401-231-8547 | |
Debra A Archetto, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 452 Putnam Pike, Greenville, RI 02828 Phone: 401-949-6212 Fax: 401-949-6217 | |
Dr. Nicholas G Brunelle, PHARM.D., R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 446 Putnam Pike, Greenville, RI 02828 Phone: 401-949-1848 Fax: 401-949-1539 | |
Adam Dinitto, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 452 Putnam Pike, Greenville, RI 02828 Phone: 401-949-6212 | |
Mr. Robert Poholek, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 452 Putnam Pike, Greenville, RI 02828 Phone: 401-949-6212 Fax: 401-949-6217 |